Taking Cymbalta with Wellbutrin: Safety and Efficacy
The combination of Cymbalta (duloxetine) and Wellbutrin (bupropion) is generally safe and can be used together for depression, though monitoring for specific drug interactions and side effects is essential.
Key Safety Considerations
Drug Interaction Profile
Duloxetine is a moderate CYP2D6 inhibitor, which can increase bupropion metabolite levels 1. When duloxetine inhibits CYP2D6, it may elevate hydroxybupropion concentrations, potentially increasing dopaminergic effects 2. This interaction requires awareness but does not contraindicate combination use.
Specific Monitoring Requirements
Monitor for these potential complications:
Delirium risk: One case report documented delirium in an elderly patient 10 days after adding bupropion to duloxetine, which resolved within 3 days of bupropion discontinuation 2. This appears most relevant in elderly patients.
Seizure threshold: Bupropion lowers seizure threshold (0.1% risk) 3. Avoid this combination entirely in patients with brain metastases, history of seizures, eating disorders, or abrupt alcohol/benzodiazepine withdrawal 3.
Blood pressure elevation: Both medications can increase blood pressure 4. Monitor BP regularly, especially during dose titration.
Serotonin syndrome: While duloxetine carries this risk, bupropion does not significantly contribute to serotonergic effects, making this combination lower risk than SSRI/SNRI combinations 1.
Clinical Effectiveness
Evidence for Combination Therapy
Research supports this combination for treatment-resistant depression, though the evidence base is limited:
A retrospective study of 10 patients with treatment-resistant MDD showed significant improvement (CGI-S scores decreased from 4.4 to 2.1, p<0.0001) after 8.8 weeks of combination therapy 5. Response rate was 60%, with 30% achieving full remission.
A naturalistic study of 82 patients found statistically greater improvement at weeks 2,4, and 8 with duloxetine combination therapy compared to monotherapy 6.
However, a randomized controlled trial in atypical depression showed modest results, with only 26.1% response rate for the combination versus 21.7% for duloxetine plus placebo (not statistically significant) 7.
When to Use This Combination
Consider this combination for:
- Inadequate response to either medication alone after adequate trial (4-8 weeks at therapeutic dose) 8
- SSRI-nonresponsive depression requiring switch to alternative mechanism 9
- Sexual dysfunction from duloxetine that requires augmentation 10
- Comorbid conditions where each medication addresses different symptoms (e.g., neuropathic pain with duloxetine, smoking cessation with bupropion) 11, 3
Practical Prescribing Algorithm
Starting the Combination
If adding bupropion to existing duloxetine:
- Start bupropion SR 100-150 mg once daily in morning 12
- Increase to 150 mg twice daily after 3-7 days if tolerated 13
- Maximum 300 mg/day (avoid higher doses given CYP2D6 interaction)
If adding duloxetine to existing bupropion:
- Start duloxetine 30 mg once daily 13
- Increase to 60 mg daily after 1 week 4
- Maximum 60 mg twice daily if needed (though 60 mg daily is typical maintenance)
Common Side Effects
Expect these manageable side effects 5:
- Nausea (20% of patients)
- Dry mouth (20%)
- Jitteriness/agitation (20%)
- Insomnia (10%)
- Increased sweating (10%)
Give second bupropion dose before 3 PM to minimize insomnia 12.
Absolute Contraindications
Do not use this combination if patient has:
- Seizure disorder or conditions lowering seizure threshold 3
- Brain metastases 3
- Eating disorders (anorexia/bulimia) 14
- Concurrent MAOI use (contraindicated with both medications) 1
- Substantial alcohol use (duloxetine hepatotoxicity risk) 1
- Uncontrolled narrow-angle glaucoma (bupropion) 3
Discontinuation
Taper both medications gradually to avoid discontinuation syndrome 1. Duloxetine particularly requires slow taper due to risk of dizziness, nausea, paresthesias, and other withdrawal symptoms. Reduce dose incrementally over 2-4 weeks minimum.
Bottom Line
This combination is supported by clinical experience and limited research for treatment-resistant depression, with acceptable tolerability in most patients. The primary concerns are seizure risk (screen carefully), potential for elevated bupropion metabolites in elderly patients, and blood pressure monitoring. The combination offers complementary mechanisms (SNRI + NDRI) that may benefit patients who haven't responded to monotherapy, but requires individualized risk-benefit assessment based on patient-specific contraindications.